CYP2A6 (cytochrome P450, family 2, subfamily A, polypeptide 6)

Naoki Inui

Department of Respiratory Medicine, Hamamatsu University School of Medicine, Shizuoka, Japan (NI)

Published in Atlas Database: December 2009


DOI: 10.4267/2042/44849

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence.

© 2010 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Identity

Other names: CPA6; CYP2A; CYP2A3; CYP1IA6; P450(I); P450C2A; P450PB

HGNC (Hugo): CYP2A6

Location: 19q13.2

Note: CYP2A6 plays a major role in the oxidation of nicotine, coumarin and some pharmaceuticals in human liver microsomes. Polymorphisms in the CYP2A6 gene that affect enzyme activity have been identified.

DNA/RNA

Description

9 exons. The gene sequence: 6910 bp.

Transcription

1751 base pairs.

Protein

Note

CYP2A6 is an enzyme responsible for the metabolism of clinically used pharmaceuticals such as coumarin and valproic acid, several carcinogens such as 4-(methylnitrosamine)-1-(3-pyridyl)-1-butanone and aflatoxin B1, nicotine and for the bioactivation process of tegafur to 5-FU.

The formation of 5-FU from tegafur was inhibited over 90% by a CYP2A6 selective antibody using human liver microsomes. CYP2A6 shows large interindividual and interethnic variations in its expression levels and conversion activities, which are mainly attributed to CYP2A6 genetic polymorphisms. The expression is induced by Phenobarbital and dexamethasone.

Example of CYP2A6 function.

(A) Oxidation: CYP2A6 is responsible for converting nicotine into the inactive metabolite nicotine delta 1'(5')-iminium ion, cotinine. (B) Oxidation: Camphor is oxidized to 5-exo-hydroxycamphor. (C) Hydroxylation: CYP2A6 is an enzyme responsible for the metabolism of clinically used pharmaceuticals, tegafur. Tegafur is converted enzymatically to 5-FU to exert its antitumor activity. (D) Hydroxylation: Coumarin is hydroxylated to 7-hydroxycoumarin.
CYP2A6 (cytochrome P450, family 2, subfamily A, polypeptide 6)

**Description**

494 amino acids.

**Expression**

Liver.

**Localisation**

Endoplasmic reticulum membrane, peripheral membrane protein, microsome membrane.

**Function**

Oxidation, reduction, coumarin 7-hydroxylase activity, electron carrier activity, heme binding, iron ion binding, oxygen binding, the hydroxylation of the anti-cancer drugs.

**Homology**

Belongs to the cytochrome P450 family.

**Mutations**

Note

CYP2A6 shows large interindividual and interethnic variations in its expression levels and conversion activities, which are mainly attributed to CYP2A6 genetic polymorphisms. These alleles are derived from single nucleotide polymorphisms in the regulatory and coding regions, deletion mutations and conversions. Polymorphisms in the CYP2A6 gene affect enzyme activity. CYP2A6*2, a polymorphism that a single base mutation (1799T>A) cause an amino acid change from leucine at residue 160 to histidine, functionally shows no enzymatic activity in vivo and in vitro. While in Caucasian this type allele has been found in 1.1-3.0%, coding regions, deletion mutations and conversions.

Cancer drugs.

There are many alleles that have been listed by the Human CYP Allele Nomenclature Committee.

**Implicated in**

**Lung cancer**

Note

Polymorphisms in the CYP2A6 gene that affect enzyme activity and susceptibility to lung cancer have been identified. Smoking is regarded as the main cause of lung cancer. CYP2A6 has responsible for the conversion of nicotine to inactive metabolite cotinine. A number of studies have demonstrated that CYP2A6 genetic variations are associated with nicotine kinetics and smoking behavior. People with CYP2A6 genetic variations, poor metabolizers of CYP2A6, were less likely to be smokers and tended to smoke fewer cigarettes per day.

**Disease**

There is the possibility that CYP2A6 associated smoking-related cancer, such as lung cancer, esophageal, gastric and colorectal cancer.

**Prognosis**

Poor metabolizers of CYP2A6 were less likely to be smokers and tended to smoke fewer cigarettes.

**References**


Tyndale RF, Sellers EM. Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk. Drug Metab Dispos. 2001 Apr;29(4 Pt 2):548-52


Carter B, Long T, Cinciripini P. A meta-analytic review of the CYP2A6 genotype and smoking behavior. Nicotine Tob Res. 2004 Apr;6(2):221-7


Schoedel KA, Hoffmann EB, Rao Y, Sellers EM, Tyndale RF. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics. 2004 Sep;14(9):615-26


This article should be referenced as such: